UK approves OTC switch for LEO's Dovonex

18 August 2017 - Deborah Wilkes

Archived

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has switched LEO Pharma's Dovonex (calcipotriol) from prescription to non-prescription status following a public consultation.

Click tags below for more information on topics:

MHRA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: